Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Considering Aventis Merger; Is a "White Knight" Bid Imminent?

This article was originally published in The Pink Sheet Daily

Executive Summary

The French market regulator Autorite des Marches Financiers has asked Novartis to explore a transaction. The company signaled its intention in January to jump back into the merger fray.

You may also be interested in...



Novartis Awaits Invite To Bid On Aventis, Says Combination Is "Viable"

Novartis wants a formal invitation from the Aventis board and a "neutral position" by the French government before it enters into merger negotiations. Novartis believes there is a "business case" for the merger, which it envisions as a two-step transaction including a spin-off of "non-core" products.

US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel